Previous 10 | Next 10 |
The following slide deck was published by Kura Oncology, Inc. in conjunction with this Read more ...
SAN DIEGO, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced the appointment of Kathleen Ford as Chief Operating Officer, effective i...
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Off...
Kura Oncology, Inc. (KURA) Q2 2019 Earnings Conference Call August 01, 2019 4:30 PM ET Company Participants Pete De Spain - Vice President of Investor Relations Troy Wilson - President & Chief Executive Officer Marc Grasso - Chief Financial Officer & Chief Business Office...
The following slide deck was published by Kura Oncology, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Kura Oncology (NASDAQ: KURA ): Q2 GAAP EPS of -$0.38 beats by $0.03 . More news on: Kura Oncology, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing – – Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration – – Additional Phase 2 data in HRAS mutant HNSCC, other SCCs and AITL ant...
Kura Sushi USA (NASDAQ: KURA ) has priced its initial public offering of 2.9M Class A common stock at $14.00 per share. More news on: Kura Oncology, Inc., Read more ...
SAN DIEGO, July 25, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2019 financial results after the clos...
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 08:15:04 ET H.C. Wainwright analyst issues BUY recommendation for KURA on June 25, 2024 06:44AM ET. The previous analyst recommendation was Buy. KURA was trading at $21.08 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
– Ziftomenib induces insulin production, improves insulin sensitivity and reduces insulin resistance in preclinical model of type 2 diabetes – – Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases ...